CryoPort, Inc. (NASDAQ:CYRX) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of CryoPort, Inc. (NASDAQ:CYRX) have received an average recommendation of “Moderate Buy” from the nine research firms that are presently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $16.3750.

CYRX has been the subject of a number of recent analyst reports. KeyCorp boosted their price objective on CryoPort from $15.00 to $17.00 and gave the company an “overweight” rating in a research report on Wednesday, May 20th. Needham & Company LLC lifted their price objective on CryoPort from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Guggenheim raised their price target on shares of CryoPort from $11.00 to $12.00 and gave the stock a “buy” rating in a report on Tuesday, May 5th. BTIG Research upped their target price on shares of CryoPort from $17.00 to $25.00 and gave the company a “buy” rating in a research report on Friday. Finally, Weiss Ratings upgraded shares of CryoPort from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, May 6th.

CryoPort Price Performance

Shares of CYRX stock opened at $15.37 on Friday. The business has a fifty day moving average of $15.29 and a 200 day moving average of $11.60. CryoPort has a 1 year low of $6.69 and a 1 year high of $16.89. The firm has a market capitalization of $774.65 million, a price-to-earnings ratio of 11.39 and a beta of 1.88.

CryoPort (NASDAQ:CYRX) last released its quarterly earnings data on Monday, May 4th. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). The business had revenue of $47.80 million during the quarter, compared to analyst estimates of $44.86 million. CryoPort had a negative return on equity of 7.92% and a net margin of 41.57%. As a group, equities research analysts expect that CryoPort will post -0.85 earnings per share for the current year.

Insiders Place Their Bets

In other news, CFO Robert Stefanovich sold 169,427 shares of the firm’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $16.27, for a total transaction of $2,756,577.29. Following the sale, the chief financial officer owned 109,850 shares of the company’s stock, valued at approximately $1,787,259.50. This trade represents a 60.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Edward J. Zecchini sold 33,600 shares of the business’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $14.47, for a total value of $486,192.00. Following the sale, the insider owned 109,719 shares of the company’s stock, valued at approximately $1,587,633.93. The trade was a 23.44% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 227,641 shares of company stock worth $3,622,515 in the last 90 days. Corporate insiders own 9.50% of the company’s stock.

Hedge Funds Weigh In On CryoPort

Several large investors have recently bought and sold shares of CYRX. UBS Group AG lifted its stake in CryoPort by 112.7% in the third quarter. UBS Group AG now owns 1,331,521 shares of the company’s stock valued at $12,623,000 after buying an additional 705,649 shares during the last quarter. Millennium Management LLC grew its position in shares of CryoPort by 23.8% during the fourth quarter. Millennium Management LLC now owns 3,244,802 shares of the company’s stock worth $31,150,000 after acquiring an additional 623,896 shares during the last quarter. Jacobs Levy Equity Management Inc. grew its position in shares of CryoPort by 283.1% during the third quarter. Jacobs Levy Equity Management Inc. now owns 524,288 shares of the company’s stock worth $4,970,000 after acquiring an additional 387,440 shares during the last quarter. Mak Capital One LLC increased its holdings in shares of CryoPort by 46.6% in the 4th quarter. Mak Capital One LLC now owns 1,199,225 shares of the company’s stock valued at $11,513,000 after acquiring an additional 381,063 shares during the period. Finally, First Eagle Investment Management LLC purchased a new stake in CryoPort in the 4th quarter valued at $2,996,000. Institutional investors and hedge funds own 92.90% of the company’s stock.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.